42nd Annual Miami Breast Cancer Conference® - Abstracts | Miami Breast Cancer Conference® Abstracts Supplement | Journal | Page 3

78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients

ByCaroline Lippe,Harper Niver,W. Bradford Carter

May 1st 2025

79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

ByRebecca Martin,Angelis Vazquez-Perez,Alice Trye,Nilofer Sidhu,Lucy M. De La Cruz,Jennifer Son

April 30th 2025

81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI

ByJoseph Peterson,Bradley Figer,Poornima Saha,Frederick Howard,Erica Stringer-Reasor

April 29th 2025

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

ByDavid J. Portman,Matthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Guiseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Sarah Sammons, MD,Sherry Shen, MD,Christ Twelves,Paul V. Plourde,Senthil Damodaran

April 27th 2025

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

ByDavid J. Portman,Timothy Pluard,Jane L. Meisel, MD,Kelly Shanahan,Sarah Sammons, MD,Elizabeth Attias

April 26th 2025

88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study

ByLee Schwartzberg, MD, FACP,Omkar Marathe,Shanta Chawla,Jeffrey L. Vacirca,Kenneth Crist,Howard Franklin,Manuel Modiano

April 23rd 2025

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByBOLDSCIENCE,Pedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

ByAtilla Soran, MD, MPH,Kazim Senol,Schlomo Schneebaum,Shigeru Imoto,Carole Mathelin,Alexander Mundinger,Meltem Selam,Vahit Ozmen

April 21st 2025

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

ByZeynep Ozlem Soran,Allison Brophy,Lily Kass,Berkay Demirors,Hayeon Kim,Atilla Soran, MD, MPH,John Austin Vargo,Parul Barry

April 20th 2025

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

ByMichelle Sosa,Deirdre McNicholas,Arbelina Bebla,Seth Emont,Zhun Cao,Manu Tyagi,Craig Lipkin,Sommer Gunia

April 19th 2025

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

ByElyse Swallow,Jessica Maitland,Kirthana Sarathy,Ellen Sears,Yasir Nagarwala,Janelle DePalantino,Eric Kruep,Corey Pelletier,Sebastian Kloss,Tomer Wasserman

April 18th 2025

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

ByChia Jie Tan,Connor Willis,Trang Au,Matthew Schabath, PhD,Chenghui Li,Kristen Kelley,Xiaoqing Xu,Leah Park,Clara Lam,Sandhya Mehta,Jackie Kwong,Diana Brixner,David Stenehjem

April 17th 2025

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

ByAlexandra Vitko,Pamela K Ginex,Kelli Thoele,Qinli Lily Ma,Astra Liepa,Wambui Gathirua-Mwangi,Elyse Hall Panjic, PharmD, BCOP,Engels Chou,Jodi L Taraba,Hilary Ellis,Charlotte Clewes,Joanna de Courcy,Hope S. Rugo, MD

April 15th 2025

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

ByCharlotta Wadsten,Karuna Mittal,Pat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balasubramanyam Karanam,Walter Bell,Charles E. Cox, MS, FACS,Abigail Beard,Geza Acs,Steven C. Shivers,David J. Dabbs,Jess Savala,Mark Mentrikoski,Troy Bremer

April 14th 2025

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

ByCaroline Welsh,Nicole Taylor,Julie Cole,Manjeet Chadha

April 13th 2025

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

ByPat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Rachel Rabinovitch, MD,Julie A. Margenthaler, MD,Fredrik Warnberg,Micheal Leo,Sheila Weinmann,G. Bruce Mann,David J. Dabbs,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 12th 2025

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

ByPooja Advani, MBBS, MD,Sofia Braga,Adam M. Brufsky, MD, PhD,Karthik V. Giridhar,Erica L. Mayer, MD, MPH,Kelly E. McCann,Ruth M. O’Regan,Cristina Saura,Seth A. Wander,Georg F. Bischof,Beth H. Lowenthal,Judith D. Bebchuk,Lisa D. Eli,Brian G. Barnett,Joyce A. O’Shaughnessy,Tufia C. Haddad

April 11th 2025

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

BySarah Sammons,Rachel A. Freedman,Adam M. Brufsky,Ahmad Awada,Sara A. Hurvitz, MD,Nancy U. Lin, MD,Cristina Saura,Sheri Leung,Bethann S Hromatka

April 9th 2025

42nd Annual Miami Breast Cancer Conference® - Abstracts

78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients

79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery

81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI

82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Trending on CancerNetwork

FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

How Might CTO1681 Prevent CRS After CAR T-Cell Therapy in DLBCL?